OBJECTIVE:To confirm the therapeutic effect and mechanism of Jingui Shenqi pill(金匮肾气丸,JGSQP)on cardiorenal syndrome.METHODS:Doxorubicin was used to build heart-kidney coinjury rat model.After the modeling was com...OBJECTIVE:To confirm the therapeutic effect and mechanism of Jingui Shenqi pill(金匮肾气丸,JGSQP)on cardiorenal syndrome.METHODS:Doxorubicin was used to build heart-kidney coinjury rat model.After the modeling was completed,JGSQP gavage intervention was performed.The cardiac function of rats in each group was evaluated by ultrasound detection.Serum of rats was collected and examined for markers of heart and kidney damage.Enzyme linked immunosorbent assay detected serum inflammatory factors interleukin-1β(IL-1β),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)expression.Quantitative real-time polymerase chain reaction(PCR)and Western blot detected the changes of related genes and proteins.RESULTS:JGSQP significantly increased left ventricular ejection fraction(EF)and left ventricular shortening fraction(FS)values,decreased the heart and kidney damage markers and fibrosis levels(P<0.05).Furthermore,it can reduce IL-1β,IL-6,and TNF-αinflammatory expression(P<0.05).Mechanistically,JGSQP significantly inhibited the expression of key genes and proteins of mitogen-activated protein kinase(MAPK)signaling pathway(P<0.05).CONCLUSIONS:Jingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.展开更多
基金Supported by Shanghai Putuo District Health System Science and Technology Innovation Project:Study on the Effect and Mechanism of Jinkui Shenqi Pills on Renal Water Metabolism via provirus integration site for moloney murine leukemia virus 3/aquaporin 2 Regulation (No. PTKWS202104)Chengdu University of Traditional Chinese Medicine "Xinglin Scholar" Discipline Talent Research Enhancement Plan:Based on provirus integration site for moloney murine leukemia virus 3 to Explore the Molecular Mechanism of Jingui Shenqi pill in Regulating Water Metabolism in Renal Tubular Cells (No. YYZX2022165)the Clinical Advantage Discipline of Health System of Putuo District in Shanghai (2019ysxk01)
文摘OBJECTIVE:To confirm the therapeutic effect and mechanism of Jingui Shenqi pill(金匮肾气丸,JGSQP)on cardiorenal syndrome.METHODS:Doxorubicin was used to build heart-kidney coinjury rat model.After the modeling was completed,JGSQP gavage intervention was performed.The cardiac function of rats in each group was evaluated by ultrasound detection.Serum of rats was collected and examined for markers of heart and kidney damage.Enzyme linked immunosorbent assay detected serum inflammatory factors interleukin-1β(IL-1β),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)expression.Quantitative real-time polymerase chain reaction(PCR)and Western blot detected the changes of related genes and proteins.RESULTS:JGSQP significantly increased left ventricular ejection fraction(EF)and left ventricular shortening fraction(FS)values,decreased the heart and kidney damage markers and fibrosis levels(P<0.05).Furthermore,it can reduce IL-1β,IL-6,and TNF-αinflammatory expression(P<0.05).Mechanistically,JGSQP significantly inhibited the expression of key genes and proteins of mitogen-activated protein kinase(MAPK)signaling pathway(P<0.05).CONCLUSIONS:Jingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.
